MA-NEC-ENERGY-SOLUTIONS
NEC Energy Solutions, Inc. (NEC ES), announced today it will provide 100MW of energy storage in Northern Ireland for the Gore Street Energy Storage Fund (GSF) and project developer Low Carbon. The 100MW of energy storage will comprise two 50MW projects located in Drumkee, County Tyrone and Mullavilly, County Armagh. The two projects, which are currently under construction, are the largest projects to date in Northern Ireland and are expected to derive revenue from the new Irish “Delivering a Secure Sustainable Electricity System” (DS3) program.
The System Operator of Northern Ireland has indicated that running the power system with increasingly high levels of renewable energy is a major challenge due to the intermittent nature of wind power and its technical characteristics. The purpose of the DS3 program is to enable Ireland to meet its target of 75% non-synchronous and renewable (i.e. wind and solar) electricity across the all-island network. The DS3 market consists of both fixed and standard contracts available across the Irish grid in both the Republic of Ireland and Northern Ireland.
“Northern Ireland has made tremendous progress adopting renewable energy. Last year 44% of electricity consumption was generated by renewable resources. This easily beats Northern Ireland’s renewable target of 40% and occurred one year ahead of its 2020 deadline. Energy storage, via the DS3 program makes more of this possible”, said Steve Fludder, CEO of NEC Energy Solutions. “We are pleased to extend our partnership with Gore Street Capital. We invested in the Gore Street Energy Storage Fund and we look forward to working with Gore Street Capital on these and future projects. We also have excellent experience with Low Carbon operating and maintaining their two projects in the UK and we’re eager to collaborate with them in Northern Ireland.”
NEC is providing turnkey engineering, procurement and construction (EPC) including its GSS® end-to-end grid storage solution and its AEROS® controls system, NEC’s proprietary energy storage control software. Both 50MW projects will be completed and commissioned in Q1 2021. This transaction marks the second tranche of projects that NEC has been awarded by both Gore Street and Low Carbon.
“We are pleased to award this important EPC contract to NEC Energy Solutions, one of Gore Street’s long-term strategic partners, following a significant competitive tender process. We chose NEC Energy Solutions because they have offered the optimal commercial and technical proposal,” commented Alex O’Cinneide, CEO of Gore Street Capital, the investment manager of Gore Street Energy Storage Fund PLC. “We look forward to working once again with NEC Energy Solutions on these significant projects, among the largest of their kind in Ireland. As investment in sources of volatile renewable generation to supply the grid in Ireland continues to increase, supported in particular by excellent wind generation potential, assets such as these will form a major step in advancing Ireland’s climate change objectives.”
About NEC Energy Solutions
NEC Energy Solutions designs, manufactures, and integrates smart energy storage solutions for the electric grid and applications with critical power needs. Its megawatt-scale energy storage and control systems provide greater stability to the grid while maximizing renewable generation, while in telecom, datacenter, and other industrial applications, its high performance lithium-ion battery systems provide better value than traditional lead-acid batteries in tough, critical power applications. Learn more at www.neces.com .
About Gore Street Energy Storage Fund Plc.
Gore Street Energy Storage Fund is the first publicly traded fund established to provide investors with a sustainable and attractive dividend over the long term by investing in a diversified portfolio of utility scale energy storage projects primarily located in the UK, North America and Western Europe. The fund went public on May 25, 2018 on the London Stock Exchange.
About Gore Street Capital
GSC is a private equity firm with a leading renewable investment expertise. Established in 2013, GS has provided a platform to acquire, develop and manage global renewable energy and has a highly experience management team. Gore Street has some energy storage experience – they have been behind the Cleveland Potash project in North Yorkshire, the Lower Road project in Brentwood, Essex and the Port of Tilbury project co-located with London’s Port of Tilbury. All projects included NEC Energy Solutions hardware and software.
NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners.
©2020 NEC Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005403/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom